1. Monoamine oxidase type B (MAO-B) is the enzyme primarily responsible for which of the following actions in the striatum and substantia nigra under normal physiological conditions?
A) Synthesizing dopamine from tyrosine via hydroxylation
B) Oxidatively deaminating dopamine to limit the duration of dopaminergic neurotransmission
C) Methylating levodopa to form 3-O-methyldopa in the peripheral circulation
D) Converting dopamine to norepinephrine via beta-hydroxylation
E) Transporting dopamine into presynaptic vesicles for storage and release
ANSWER: B
Rationale:
Option B is correct. MAO-B catalyzes the oxidative deamination of dopamine within the striatum and substantia nigra, converting it first to dihydroxyphenylacetic acid (DOPAC) and ultimately to homovanillic acid. This catabolism terminates dopaminergic neurotransmission by reducing the available pool of dopamine at the synapse. In Parkinson's disease (PD), where striatal dopamine is already severely depleted, MAO-B inhibition prolongs the synaptic availability of residual dopamine and dopamine synthesized from exogenous levodopa, which is the pharmacological basis for using this drug class as an adjunct.
Option A: Option A is incorrect because dopamine synthesis from tyrosine is a two-step process catalyzed by tyrosine hydroxylase and aromatic amino acid decarboxylase — MAO-B plays no role in synthesis.
Option C: Option C is incorrect because peripheral methylation of levodopa to 3-O-methyldopa is performed by catechol-O-methyltransferase (COMT), not MAO-B; this is the mechanism targeted by COMT inhibitors such as entacapone and opicapone.
Option D: Option D is incorrect because the conversion of dopamine to norepinephrine is catalyzed by dopamine beta-hydroxylase, an enzyme expressed in noradrenergic neurons and the adrenal medulla — it is not an MAO-B function.
Option E: Option E is incorrect because vesicular storage of dopamine is mediated by the vesicular monoamine transporter 2 (VMAT2), not MAO-B; VMAT2 is the target of valbenazine and deutetrabenazine, which are used in tardive dyskinesia, not Parkinson's disease.
2. A patient with Parkinson's disease is being started on rasagiline for motor fluctuations. The patient asks whether they need to follow the strict low-tyramine diet that their late father had to observe when he was treated with phenelzine decades ago. Which of the following best explains why the low-tyramine dietary restriction is not required at standard therapeutic doses of rasagiline?
A) Rasagiline undergoes complete hepatic first-pass metabolism, preventing it from reaching systemic circulation in amounts sufficient to affect peripheral enzymes
B) Rasagiline selectively inhibits MAO-B located in the striatum, and MAO-B is the isoform responsible for metabolizing tyramine in the gut and liver
C) Dietary tyramine is metabolized exclusively by aromatic amino acid decarboxylase in the intestinal wall before it can reach the liver or systemic circulation
D) Selective MAO-B inhibitors leave MAO-A essentially intact at therapeutic doses, and it is MAO-A in the gut and liver that metabolizes tyramine and prevents its systemic absorption
E) Rasagiline is a reversible inhibitor, so tyramine can competitively displace it from the enzyme during peak dietary tyramine absorption
ANSWER: D
Rationale:
Option D is correct. The critical pharmacological distinction between selective MAO-B inhibitors and older non-selective monoamine oxidase inhibitors (MAOIs) such as phenelzine is isoform selectivity. MAO-A, found predominantly in the gastrointestinal tract and liver, is responsible for the first-pass catabolism of dietary tyramine. When MAO-A is inhibited — as it is by phenelzine and other non-selective MAOIs — ingested tyramine is absorbed intact, reaches the systemic circulation, and triggers norepinephrine release from sympathetic nerve terminals, producing potentially life-threatening hypertensive crisis (the "cheese effect"). Selective MAO-B inhibitors, at approved therapeutic doses, leave MAO-A function essentially intact. Tyramine continues to be metabolized normally by gut and hepatic MAO-A, so dietary restrictions are not required at standard doses.
Option A: Option A is incorrect because rasagiline is not characterized by complete first-pass elimination; it is well absorbed and reaches systemic circulation, where it exerts its MAO-B inhibitory effect in the CNS.
Option B: Option B is incorrect because tyramine is metabolized by MAO-A, not MAO-B; stating that MAO-B handles tyramine inverts the isoform specificity that is the entire basis for selective MAO-B inhibitor safety.
Option C: Option C is incorrect because tyramine is not metabolized by aromatic amino acid decarboxylase; that enzyme converts levodopa to dopamine and DOPA to other catecholamines — it does not catabolize tyramine.
Option E: Option E is incorrect because while safinamide is indeed a reversible MAO-B inhibitor, rasagiline is an irreversible, covalent inhibitor — and in any case, reversibility at MAO-B is irrelevant to tyramine safety, which depends on MAO-A function remaining intact.
3. A 71-year-old man with Parkinson's disease reports difficulty falling asleep since his neurologist added selegiline to his carbidopa-levodopa regimen three weeks ago. He denies any new anxiety or agitation during the day but says he is still mentally alert at midnight when he would normally be asleep. Which of the following pharmacological properties of selegiline is most directly responsible for this adverse effect?
A) Hepatic first-pass metabolism of selegiline produces l-methamphetamine and l-amphetamine as active metabolites, which exert CNS stimulant effects that interfere with sleep onset
B) Selegiline inhibits MAO-B irreversibly in the brainstem, reducing the catabolism of serotonin and thereby suppressing the normal nocturnal rise in melatonin synthesis
C) Selegiline's long plasma half-life causes accumulation of the parent compound over three weeks, producing sustained dopaminergic overstimulation of the arousal pathways
D) Selegiline blocks reuptake of norepinephrine at the locus coeruleus, increasing wakefulness through direct adrenergic activation of cortical arousal circuits
E) Selegiline competitively inhibits the COMT enzyme in the basal ganglia, prolonging levodopa exposure and indirectly increasing dopaminergic drive to arousal centers
ANSWER: A
Rationale:
Option A is correct. When selegiline is administered as a standard oral tablet, it undergoes extensive hepatic first-pass metabolism. Its primary metabolites are l-methamphetamine and l-amphetamine — both pharmacologically active CNS stimulants. These amphetamine derivatives are responsible for the insomnia and, in some patients, agitation or anxiety that limit selegiline tolerability, particularly in older individuals. This metabolite burden is sufficiently predictable that dosing guidelines explicitly recommend scheduling selegiline in the morning to minimize the evening stimulant effect; evening or late-afternoon dosing is considered a prescribing error in the context of this adverse effect.
Option B: Option B is incorrect because MAO-B inhibition primarily affects dopamine catabolism in the striatum, not serotonin in the brainstem to a clinically meaningful degree at selective doses, and reduced serotonin catabolism would not suppress melatonin — if anything, it would tend to support serotonin availability, which is a precursor to melatonin.
Option C: Option C is incorrect because selegiline itself does not have an exceptionally long plasma half-life; its insomnia effect is attributable to amphetamine metabolites rather than accumulation of the parent drug.
Option D: Option D is incorrect because selegiline is not a norepinephrine reuptake inhibitor; this mechanism describes drugs such as atomoxetine or tricyclic antidepressants with prominent noradrenergic activity.
Option E: Option E is incorrect because selegiline is an MAO-B inhibitor, not a COMT inhibitor; COMT inhibition is the mechanism of entacapone, opicapone, and tolcapone, which are a distinct class of levodopa adjuncts.
4. A neurologist is deciding between selegiline and rasagiline as an adjunct to carbidopa-levodopa for a 68-year-old patient with Parkinson's disease who already has mild anxiety and reports fragmented sleep. Which of the following properties of rasagiline makes it the more appropriate choice for this patient compared to selegiline?
A) Rasagiline is a reversible MAO-B inhibitor, so its effects on the CNS can be rapidly terminated if neuropsychiatric symptoms emerge
B) Rasagiline has a longer plasma half-life than selegiline, allowing once-daily dosing that minimizes peak plasma fluctuations associated with stimulant side effects
C) Rasagiline is metabolized to aminoindan, a compound without amphetamine-like activity, avoiding the CNS stimulant metabolites that contribute to insomnia and anxiety with selegiline
D) Rasagiline is administered by the sublingual route, bypassing hepatic first-pass metabolism and preventing the formation of any active metabolites
E) Rasagiline selectively inhibits MAO-A in addition to MAO-B at standard doses, reducing serotonin catabolism and producing an anxiolytic effect that counteracts any stimulant metabolites
ANSWER: C
Rationale:
Option C is correct. The primary tolerability advantage of rasagiline over selegiline is its metabolite profile. Selegiline is biotransformed to l-methamphetamine and l-amphetamine, pharmacologically active CNS stimulants that produce insomnia, agitation, and anxiety as recognized adverse effects — effects that are particularly problematic in older patients and those with pre-existing neuropsychiatric symptoms. Rasagiline, by contrast, is metabolized via CYP1A2 to aminoindan, a compound with no amphetamine-like pharmacological activity. This difference in metabolite character makes rasagiline substantially better tolerated neuropsychiatrically, and it is a key clinical reason to prefer rasagiline in a patient who already has anxiety and sleep disruption.
Option A: Option A is incorrect because rasagiline is an irreversible, covalent MAO-B inhibitor — recovery of MAO-B activity requires new enzyme synthesis over approximately two to three weeks. Safinamide, not rasagiline, is the reversible MAO-B inhibitor in the class.
Option B: Option B is incorrect because while rasagiline's once-daily dosing is a practical advantage, the tolerability benefit in this patient specifically is not about half-life or peak plasma fluctuations — it is about the absence of amphetamine metabolites that are pharmacologically responsible for the neuropsychiatric effects.
Option D: Option D is incorrect because rasagiline is administered as a standard oral tablet, not sublingually. The sublingual or orally disintegrating tablet formulation was developed for selegiline (as the selegiline ODT), precisely to reduce first-pass amphetamine metabolite formation.
Option E: Option E is incorrect because rasagiline at its approved dose of 1 mg daily is a selective MAO-B inhibitor that does not meaningfully inhibit MAO-A; non-selective MAO inhibition does not occur at therapeutic doses, and rasagiline does not possess anxiolytic activity as a pharmacological property.
5. The orally disintegrating tablet (ODT) formulation of selegiline was developed to address a specific pharmacokinetic limitation of the standard oral tablet. Which of the following best describes the mechanism by which the ODT formulation achieves a more favorable adverse effect profile?
A) The ODT formulation contains a prodrug of selegiline that is activated only within striatal neurons, preventing peripheral metabolite formation entirely
B) The ODT delivers selegiline via rectal absorption, circumventing gastric acid degradation and reducing the total daily dose required for MAO-B inhibition
C) The ODT formulation contains an excipient that competitively inhibits hepatic CYP2D6, reducing the conversion of selegiline to amphetamine metabolites during first-pass metabolism
D) The ODT delivers selegiline transdermally through the buccal mucosa at a controlled rate, producing steady-state plasma concentrations that are therapeutically equivalent to the standard tablet at double the dose
E) The ODT is absorbed through the buccal and sublingual mucosa, bypassing hepatic first-pass metabolism and resulting in substantially lower peak plasma concentrations of l-methamphetamine and l-amphetamine compared to the standard tablet
ANSWER: E
Rationale:
Option E is correct. The selegiline ODT was designed specifically to reduce the amphetamine metabolite burden that limits tolerability of the standard oral tablet formulation. When the ODT dissolves in the mouth, selegiline is absorbed primarily through the buccal and sublingual mucosa, entering the systemic circulation directly without passing through the hepatic portal system. This route largely bypasses the hepatic first-pass metabolism that converts selegiline to l-methamphetamine and l-amphetamine. The result is that adequate MAO-B inhibition is achieved at a lower dose (1.25 mg twice daily, before breakfast and lunch) with substantially reduced peak amphetamine metabolite concentrations, improving neuropsychiatric tolerability in patients prone to insomnia or agitation. Note that even the ODT carries the morning-and-lunch timing restriction, because some amphetamine metabolite exposure still occurs and evening dosing risks sleep disruption.
Option A: Option A is incorrect because selegiline is not a prodrug; it is pharmacologically active as administered and its metabolites arise from hepatic biotransformation of the intact drug, not from a prodrug activation step within neurons.
Option B: Option B is incorrect because the ODT is not administered rectally; it dissolves in the mouth and is absorbed transmucosally, and this route is chosen specifically to avoid, not circumvent, first-pass metabolism through a different anatomical pathway.
Option C: Option C is incorrect because the ODT formulation does not contain a CYP2D6 inhibitor; the reduction in amphetamine metabolites is achieved purely through the route of absorption bypassing first-pass hepatic metabolism, not through any enzyme inhibition by an excipient.
Option D: Option D is incorrect because the ODT is not a transdermal system; it dissolves in the oral cavity and absorption is transmucosal, not transdermal — and the dose is lower than the standard tablet, not double it.
6. Safinamide is approved as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations. Which of the following best distinguishes safinamide's mechanism of action from that of selegiline and rasagiline?
A) Safinamide is the only MAO-B inhibitor that also inhibits peripheral catechol-O-methyltransferase (COMT), giving it a dual effect on levodopa bioavailability
B) Safinamide combines reversible MAO-B inhibition with voltage-gated sodium channel blockade, reducing pathologically elevated glutamate release in basal ganglia circuits in addition to augmenting dopaminergic tone
C) Safinamide irreversibly inhibits both MAO-A and MAO-B at its approved dose, providing broader monoaminergic coverage than the selective agents selegiline and rasagiline
D) Safinamide acts as a dopamine reuptake inhibitor at the striatal synapse in addition to inhibiting MAO-B, providing a dual dopaminergic mechanism that extends on time more effectively than a single-mechanism agent
E) Safinamide is the only MAO-B inhibitor that crosses the blood-brain barrier and inhibits central COMT, allowing it to reduce both dopamine catabolism and levodopa methylation within the CNS
ANSWER: B
Rationale:
Option B is correct. Safinamide is mechanistically distinct within the approved MAO-B inhibitor class by virtue of two concurrent actions. First, it is a reversible, competitive inhibitor of MAO-B — unlike selegiline and rasagiline, which are irreversible, covalent inhibitors. Second, and uniquely, safinamide blocks voltage-gated sodium channels in the striatum in a state-dependent manner, reducing the pathologically elevated glutamate release that occurs in basal ganglia circuits in Parkinson's disease, particularly in patients on chronic levodopa with motor fluctuations. Excessive glutamatergic drive in the subthalamic nucleus and its projections contributes to both motor fluctuation severity and dyskinesia genesis; safinamide's anti-glutamatergic activity addresses this second pathological mechanism simultaneously. No other approved MAO-B inhibitor has this sodium channel / anti-glutamatergic property.
Option A: Option A is incorrect because safinamide does not inhibit COMT, peripherally or centrally. COMT inhibition is the mechanism of entacapone, opicapone, and tolcapone — a structurally and pharmacologically distinct drug class.
Option C: Option C is incorrect because safinamide at its approved doses of 50–100 mg daily is a selective MAO-B inhibitor; it does not meaningfully inhibit MAO-A at therapeutic exposures. Non-selective MAO inhibition would confer tyramine sensitivity and other interaction risks not observed at therapeutic safinamide doses.
Option D: Option D is incorrect because safinamide is not a dopamine reuptake inhibitor. Inhibition of the dopamine transporter is the mechanism of amphetamine-related compounds and certain stimulants; it is not a property of any approved MAO-B inhibitor, including safinamide.
Option E: Option E is incorrect because it confuses safinamide with tolcapone. Tolcapone is the COMT inhibitor that penetrates the blood-brain barrier and inhibits central COMT; safinamide inhibits MAO-B and voltage-gated sodium channels but has no COMT-inhibitory activity.
7. A 74-year-old woman with Parkinson's disease is taking rasagiline 1 mg once daily as an adjunct to carbidopa-levodopa. She develops a urinary tract infection and her physician considers prescribing ciprofloxacin. Which of the following best describes the pharmacokinetic interaction that makes this combination clinically significant?
A) Ciprofloxacin inhibits CYP3A4, which is the primary enzyme responsible for rasagiline clearance; inhibition substantially reduces rasagiline elimination and may increase the risk of non-selective MAO inhibition
B) Ciprofloxacin induces intestinal P-glycoprotein, increasing rasagiline efflux from enterocytes and reducing oral bioavailability to subtherapeutic levels
C) Ciprofloxacin competes with rasagiline for renal tubular secretion, reducing rasagiline clearance and producing plasma concentrations high enough to inhibit MAO-A in addition to MAO-B
D) Ciprofloxacin is a potent inhibitor of CYP1A2, the enzyme primarily responsible for rasagiline hepatic metabolism; co-administration substantially increases rasagiline plasma concentrations, warranting a dose reduction to 0.5 mg daily
E) Ciprofloxacin directly inhibits MAO-B by binding to the same active site as rasagiline, producing additive enzyme inhibition that amplifies dyskinesia risk in levodopa-treated patients
ANSWER: D
Rationale:
Option D is correct. Rasagiline is metabolized primarily by CYP1A2 to its major metabolite, aminoindan. Ciprofloxacin is a well-characterized potent inhibitor of CYP1A2. When these two drugs are co-administered, CYP1A2-mediated clearance of rasagiline is significantly reduced, and rasagiline plasma concentrations increase substantially above the expected range for 1 mg daily. Elevated rasagiline levels raise the risk that selectivity for MAO-B over MAO-A may be lost, potentially reinstating the tyramine interaction risk and serotonergic interaction risks associated with less selective MAO inhibition. The prescribing information for rasagiline addresses this by recommending a dose reduction to 0.5 mg daily when a strong CYP1A2 inhibitor such as ciprofloxacin cannot be avoided. Other strong CYP1A2 inhibitors — notably fluvoxamine — carry the same interaction warning.
Option A: Option A is incorrect because CYP3A4 is not the primary metabolic pathway for rasagiline; CYP1A2 is the relevant isoform. Confusing the two isoforms is a common distractor but reflects an inversion of the actual pharmacokinetic data.
Option B: Option B is incorrect because rasagiline's interaction profile is driven by CYP1A2 metabolism, not by P-glycoprotein-mediated efflux; ciprofloxacin's relevant enzyme interaction is CYP1A2 inhibition, not P-glycoprotein induction.
Option C: Option C is incorrect because rasagiline clearance is primarily hepatic via CYP1A2, not via renal tubular secretion; the mechanism of the ciprofloxacin interaction is enzymatic, not renal.
Option E: Option E is incorrect because ciprofloxacin does not bind to or inhibit MAO-B; it is a fluoroquinolone antibiotic whose relevant pharmacokinetic property in this context is its potent CYP1A2 inhibition, not any direct monoamine oxidase interaction.
8. The PRESTO trial evaluated rasagiline in patients with Parkinson's disease already receiving levodopa and experiencing motor fluctuations. Which of the following correctly describes the primary finding of this trial?
A) Rasagiline 1 mg daily significantly reduced total daily off time by approximately 1.85 hours compared to placebo, establishing its efficacy as a levodopa adjunct in patients with motor fluctuations
B) Rasagiline 1 mg daily demonstrated a neuroprotective effect by showing that early-start patients maintained superior motor function at 72 weeks compared to patients who began rasagiline 36 weeks later
C) Rasagiline 1 mg daily significantly reduced the frequency of dyskinesia in levodopa-treated patients compared to placebo, establishing its role as a first-line anti-dyskinetic agent in advanced Parkinson's disease
D) Rasagiline 2 mg daily as monotherapy in previously untreated patients significantly improved UPDRS motor scores compared to placebo at one year, establishing early monotherapy efficacy
E) Rasagiline 0.5 mg and 1 mg daily both reduced wearing-off episodes equally compared to placebo, with no dose-dependent difference in off-time reduction observed across the trial arms
ANSWER: A
Rationale:
Option A is correct. The PRESTO trial (Parkinson Study Group, 2005) was a randomized, double-blind, placebo-controlled trial of rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations. Patients receiving rasagiline 1 mg daily experienced a reduction in total daily off time of approximately 1.85 hours compared to placebo, a statistically significant and clinically meaningful difference. The 0.5 mg dose also reduced off time significantly compared to placebo, though the magnitude was somewhat less than with 1 mg. The PRESTO trial was a pivotal study supporting rasagiline's indication as adjunctive therapy and remains a key reference for its efficacy in the levodopa-treated patient population.
Option B: Option B is incorrect because the description of early-start versus delayed-start design and the 72-week comparison corresponds to the ADAGIO trial, not PRESTO. ADAGIO used a delayed-start methodology to investigate potential neuroprotection with rasagiline, and its conclusions on neuroprotection were inconclusive.
Option C: Option C is incorrect because the PRESTO trial did not demonstrate a reduction in dyskinesia frequency — in fact, dyskinesia was reported as a more frequent adverse event in the rasagiline group than in placebo recipients, reflecting the augmented dopaminergic exposure that the drug produces when added to a levodopa regimen.
Option D: Option D is incorrect because the description of monotherapy in previously untreated patients corresponds to the TEMPO trial (Parkinson Study Group, 2002), which established rasagiline efficacy as an initial treatment in early PD, not as an adjunct to levodopa.
Option E: Option E is incorrect because a dose-dependent difference was observed in the PRESTO trial; the 1 mg dose produced a larger reduction in off time than the 0.5 mg dose, confirming a dose-response relationship for rasagiline's adjunctive effect.
9. The ADAGIO trial investigated rasagiline using a delayed-start design in which patients were randomized to begin rasagiline immediately or 36 weeks later. Which of the following best describes the trial's conclusion regarding neuroprotection?
A) The ADAGIO trial definitively established that rasagiline 1 mg daily slows the underlying neurodegenerative process in Parkinson's disease, leading to its approval as a neuroprotective agent
B) The ADAGIO trial showed that rasagiline 2 mg daily met all three pre-specified primary endpoints for a neuroprotection claim, while the 1 mg dose showed only symptomatic benefit
C) The ADAGIO trial produced inconclusive results: the 1 mg early-start group met all three pre-specified primary endpoints, but the 2 mg dose did not, and this unexplained absence of a dose-response relationship left the neuroprotection question unresolved under the trial's own criteria
D) The ADAGIO trial was terminated early when an interim analysis showed that the delayed-start group had significantly worse motor outcomes than early-start patients at 36 weeks, providing unambiguous evidence of neuroprotection
E) The ADAGIO trial demonstrated that neither the 1 mg nor the 2 mg dose of rasagiline altered the rate of motor decline compared to placebo, effectively ruling out a neuroprotective effect for the drug
ANSWER: C
Rationale:
Option C is correct. The ADAGIO trial (Olanow et al., 2009) was a large, well-designed randomized controlled trial using a delayed-start methodology intended to separate neuroprotective from purely symptomatic effects of rasagiline. The pre-specified analysis required that the early-start group demonstrate superiority on all three hierarchical primary endpoints at 72 weeks for a neuroprotection conclusion to be supported. The 1 mg early-start group met all three pre-specified primary endpoints; the 2 mg dose, however, did not (it failed the endpoint comparing change in UPDRS score from baseline to week 72). A positive result at the lower dose with a negative result at the higher dose is internally discrepant: the absence of a dose-response relationship, the possibility that the 1 mg result was a false positive, and the concern that the higher dose's larger symptomatic effect may have masked a delayed-start difference together meant the finding could not be accepted as establishing a disease-modifying effect. The neuroprotection conclusion was therefore inconclusive under the trial's own criteria. ADAGIO remains the most rigorous clinical evidence bearing on rasagiline neuroprotection, and it does not establish it. The question of whether any pharmacological agent meaningfully slows the underlying neurodegenerative process in Parkinson's disease remains open.
Option A: Option A is incorrect because ADAGIO did not establish neuroprotection and rasagiline has no approved neuroprotective indication; this option inverts the trial's inconclusive finding into a positive conclusion that is not supported by the data or the regulatory record.
Option B: Option B is incorrect because it reverses the actual findings of the two doses — it was the 1 mg dose that met all three primary endpoints, while the 2 mg dose failed to meet all three; characterizing the 2 mg dose as having met all endpoints and the 1 mg dose as showing only symptomatic benefit is factually backwards.
Option D: Option D is incorrect because the ADAGIO trial was not terminated early; it completed its planned design, and the comparison at 36 weeks was a pre-specified secondary analysis embedded in the delayed-start methodology, not an interim analysis that led to early termination.
Option E: Option E is incorrect because the ADAGIO trial did not produce a result that definitively rules out neuroprotection; the 1 mg dose met all three endpoints while the 2 mg dose did not, yielding an inconclusive overall result rather than a null finding across both doses.
10. A patient with Parkinson's disease is started on entacapone as an adjunct to their carbidopa-levodopa regimen. The patient asks why they need to take a separate pill with each levodopa dose rather than just once in the morning. Which of the following correctly explains the pharmacokinetic basis for this dosing requirement?
A) Entacapone has a very long half-life that requires once-daily dosing to prevent accumulation, but it must be given at the same time as levodopa because food significantly reduces its bioavailability
B) Entacapone undergoes autoinhibition of its own metabolism after the first dose, making it necessary to stagger doses with each levodopa administration to avoid COMT enzyme saturation
C) Entacapone requires co-administration with carbidopa to be activated; because carbidopa is only present in the bloodstream transiently after each levodopa dose, entacapone must be timed identically
D) Entacapone penetrates the blood-brain barrier slowly and requires repeated dosing throughout the day to maintain sufficient central COMT inhibition to extend levodopa's duration of action in the striatum
E) Entacapone has a plasma half-life of approximately two hours, meaning each dose provides only a few hours of COMT inhibition; dosing with every levodopa administration is required to maintain continuous peripheral COMT inhibition across the day
ANSWER: E
Rationale:
Option E is correct. Entacapone's short plasma half-life of approximately two hours is the pharmacokinetic property that dictates its dosing frequency. Each 200 mg dose provides only a few hours of meaningful catechol-O-methyltransferase (COMT) inhibition before plasma concentrations fall below effective levels and COMT activity recovers. To maintain continuous suppression of peripheral levodopa methylation to 3-O-methyldopa throughout the day, entacapone must be taken with every levodopa/carbidopa dose — typically three to eight times daily depending on the patient's levodopa schedule. This is the principal practical inconvenience of entacapone compared to opicapone, which achieves greater than 95% COMT inhibition for 24 hours from a single bedtime dose due to its near-covalent binding to the enzyme and very slow dissociation rate.
Option A: Option A is incorrect because entacapone has a short half-life, not a long one; once-daily dosing would provide only a brief window of COMT inhibition and would leave most of the day without meaningful peripheral COMT blockade, allowing ongoing levodopa methylation and wearing-off symptoms.
Option B: Option B is incorrect because entacapone does not undergo autoinhibition; there is no feedback mechanism by which entacapone inhibits its own metabolism, and COMT enzyme saturation is not the rationale for the dosing frequency — short duration of action is.
Option C: Option C is incorrect because entacapone is pharmacologically active as administered and does not require carbidopa for activation; its site of action is peripheral COMT, and its mechanism is independent of whether carbidopa is present or absent in the circulation.
Option D: Option D is incorrect because entacapone acts exclusively at peripheral COMT and does not penetrate the blood-brain barrier in significant quantities; its mechanism of extending levodopa effect is peripheral (reducing 3-OMD formation and increasing levodopa AUC), not central COMT inhibition, which is the distinction that separates entacapone from tolcapone.
11. A patient with Parkinson's disease calls the clinic two days after starting entacapone, alarmed because his urine has turned orange-brown. He is otherwise feeling well, has no abdominal pain, and liver function tests drawn at his last visit were normal. Which of the following is the most appropriate response?
A) Entacapone should be discontinued immediately and the patient referred for urgent hepatology evaluation, as orange urine discoloration is an early sign of the drug-induced fulminant hepatic failure associated with this class
B) The orange-brown urine discoloration is a harmless side effect caused by catechol metabolites of entacapone; the patient should be reassured that this is expected, requires no intervention, and is not a sign of liver toxicity
C) The patient should be advised to increase fluid intake substantially, as orange urine with entacapone indicates drug crystallization in the renal tubules that can cause obstructive nephropathy if not diluted
D) The discoloration indicates that entacapone's COMT-inhibitory effect is too potent for this patient; the dose should be reduced from 200 mg per levodopa dose to 100 mg to decrease the catechol metabolite load
E) Orange urine discoloration with entacapone signals a pharmacokinetic interaction with carbidopa-levodopa, in which excessive 3-O-methyldopa accumulation is saturating renal tubular secretion and producing the visible color change
ANSWER: B
Rationale:
Option B is correct. Orange-brown discoloration of urine is a well-documented, harmless side effect of entacapone. The discoloration is produced by catechol metabolites of the drug excreted in urine, not by any toxic process affecting the kidney or liver. This adverse effect is sufficiently predictable and alarming to patients who have not been forewarned that proactive patient counseling is considered standard practice at the time entacapone is initiated. Clinicians should explicitly tell patients before they leave the office that their urine may change color and that this is benign and expected. In the absence of symptoms suggesting hepatotoxicity — such as jaundice, right upper quadrant pain, nausea, or elevated transaminases — the discoloration requires no investigation or dose change.
Option A: Option A is incorrect because urine discoloration with entacapone is not a sign of hepatotoxicity; it is a benign excretory phenomenon. The COMT inhibitor associated with serious hepatotoxicity risk, including fatal fulminant hepatic failure, is tolcapone — not entacapone. Entacapone does not carry a hepatotoxicity warning and does not require routine liver function monitoring.
Option C: Option C is incorrect because entacapone does not crystallize in the renal tubules; the orange color is caused by catechol metabolites in the urine, not crystallopathy, and increased fluid intake is not indicated for this purpose.
Option D: Option D is incorrect because the orange urine is not dose-dependent in a way that signals excess COMT inhibition requiring dose adjustment; the 200 mg per levodopa dose standard is fixed, and discoloration does not indicate pharmacodynamic excess.
Option E: Option E is incorrect because the color change has nothing to do with 3-O-methyldopa accumulation or renal tubular secretion saturation; it is produced by the chromogenic properties of entacapone's catechol metabolites in an aqueous environment, which is why it appears in urine.
12. Opicapone is a third-generation COMT inhibitor approved for adjunctive use in Parkinson's disease. Which of the following properties best explains why opicapone can be administered once daily at bedtime rather than with each levodopa dose as entacapone requires?
A) Opicapone binds to COMT with near-covalent affinity and dissociates extremely slowly, allowing a single 50 mg bedtime dose to maintain greater than 95% COMT inhibition for 24 hours
B) Opicapone has a plasma half-life of 18 to 24 hours because it undergoes enterohepatic recirculation, allowing once-daily dosing based on pharmacokinetic persistence of the parent drug
C) Opicapone inhibits both peripheral and central COMT, and its central action provides sustained levodopa exposure within the striatum even after peripheral COMT inhibition has waned
D) Opicapone is a prodrug that is converted to its active metabolite slowly over 12 to 16 hours in the liver, producing a controlled-release pharmacokinetic profile that sustains COMT inhibition throughout the day
E) Opicapone's once-daily dosing is possible because its inhibition of COMT is competitive and rapidly reversible, allowing the enzyme to recover between levodopa doses and preventing excessive dopaminergic exposure
ANSWER: A
Rationale:
Option A is correct. Opicapone's once-daily dosing is made possible by its exceptional binding affinity for COMT. Unlike entacapone, which has a conventional pharmacokinetic profile with a plasma half-life of approximately two hours and reversible COMT inhibition that wanes within a few hours of each dose, opicapone binds to the COMT enzyme with near-covalent affinity and dissociates at an extremely slow rate. This pharmacodynamic property — tight, long-lasting enzyme binding — means that a single 50 mg dose administered at bedtime produces greater than 95% COMT inhibition that persists for approximately 24 hours, far outlasting the plasma half-life of the drug itself. Bedtime dosing is chosen to avoid the need for coordination with individual levodopa doses and to reduce the risk of peak-dose dopaminergic adverse effects in the early post-dose period. The BIPARK-I and BIPARK-II trials confirmed opicapone's efficacy and tolerability with this once-daily regimen.
Option B: Option B is incorrect because opicapone's duration of action is not due to pharmacokinetic persistence of the parent compound via enterohepatic recirculation; it is due to the pharmacodynamic property of near-covalent enzyme binding that sustains COMT inhibition well beyond plasma drug clearance.
Option C: Option C is incorrect because opicapone, like entacapone, acts exclusively at peripheral COMT and does not meaningfully penetrate the blood-brain barrier; inhibition of central COMT is a property of tolcapone, not opicapone.
Option D: Option D is incorrect because opicapone is not a prodrug; it is pharmacologically active as administered and its extended duration is a pharmacodynamic rather than pharmacokinetic phenomenon.
Option E: Option E is incorrect because opicapone's binding is near-covalent and extremely slow to reverse, which is the opposite of rapid reversibility; once-daily dosing works because the inhibition is prolonged, not because it reverses and resets between doses.
13. Which of the following correctly describes the site of action that distinguishes tolcapone from entacapone and opicapone within the COMT inhibitor class?
A) Tolcapone acts exclusively at peripheral COMT in the gastrointestinal wall, where it prevents first-pass levodopa methylation before the drug enters the portal circulation
B) Tolcapone inhibits COMT only within the liver, reducing the hepatic extraction of levodopa and increasing the fraction of each oral dose that reaches systemic circulation
C) Tolcapone and entacapone have identical sites of action — both inhibit only peripheral COMT — but tolcapone is distinguished by its more potent binding affinity, which produces a larger increase in levodopa AUC per dose
D) Unlike entacapone and opicapone, which act exclusively at peripheral COMT, tolcapone inhibits both peripheral and central COMT, giving it a larger pharmacodynamic effect on levodopa bioavailability and on brain dopamine metabolism
E) Tolcapone acts exclusively at central COMT within the striatum, leaving peripheral COMT intact; its central action directly increases the fraction of levodopa converted to dopamine within the brain rather than methylated to 3-O-methyldopa
ANSWER: D
Rationale:
Option D is correct. The site-of-action distinction within the COMT inhibitor class is one of its most clinically important pharmacological features. Entacapone and opicapone act exclusively at peripheral COMT — they reduce the conversion of levodopa to 3-O-methyldopa (3-OMD) in the gut and peripheral tissues, thereby increasing the levodopa AUC reaching the brain, but they do not penetrate the blood-brain barrier in clinically significant quantities and do not affect central dopamine catabolism via COMT. Tolcapone, in contrast, penetrates the blood-brain barrier and inhibits COMT both peripherally and centrally. This dual site of action gives tolcapone a larger total pharmacodynamic effect on dopaminergic exposure — it both increases levodopa delivery to the brain and reduces central dopamine catabolism by COMT within the striatum. This additional potency is part of what made tolcapone initially attractive, and it is also part of why the drug carries a more complex risk profile, culminating in the post-marketing discovery of fatal fulminant hepatic failure and the subsequent black-box warning.
Option A: Option A is incorrect because entacapone — not tolcapone — is the agent that acts at peripheral COMT, and the description of action exclusively at the gastrointestinal wall is an oversimplification; peripheral COMT inhibition occurs throughout systemic tissues, not only in the gut wall.
Option B: Option B is incorrect because tolcapone's mechanism is not confined to hepatic COMT; its peripheral inhibition is systemic and its central inhibition extends to the striatum.
Option C: Option C is incorrect because tolcapone and entacapone do not share identical sites of action — this is the specific factual distinction being tested; tolcapone's central COMT inhibition is its defining pharmacological difference from entacapone and opicapone.
Option E: Option E is incorrect because tolcapone does not act exclusively at central COMT; it inhibits both peripheral and central COMT simultaneously, and its peripheral action — increasing levodopa AUC — is an important part of its mechanism.
14. A neurologist is considering adding tolcapone to the regimen of a patient with Parkinson's disease who has failed to obtain adequate wearing-off control with entacapone and opicapone. Which of the following correctly describes the mandatory liver function monitoring schedule required by tolcapone's black-box warning?
A) Liver function tests (LFTs) are required at baseline and then annually thereafter; tolcapone must be discontinued if alanine aminotransferase (ALT) or aspartate aminotransferase (AST) rises above five times the upper limit of normal
B) LFTs are required every six months for the first two years of tolcapone therapy, after which annual monitoring is sufficient if values have remained consistently normal throughout the initial period
C) LFTs are required at baseline, every two weeks for the first six months, monthly for the next six months, and then every eight weeks thereafter; the drug must be discontinued immediately if ALT or AST exceeds two times the upper limit of normal
D) LFTs are required only if the patient develops symptoms of liver injury such as jaundice, dark urine, or right upper quadrant pain; routine monitoring is not mandated because hepatotoxicity with tolcapone is idiosyncratic and unpredictable
E) LFTs are required at baseline and monthly for the entire duration of tolcapone therapy with no reduction in frequency permitted; the drug is discontinued if transaminases exceed the upper limit of normal at any measurement
ANSWER: C
Rationale:
Option C is correct. Tolcapone carries a black-box warning for potentially fatal, acute fulminant hepatic failure, based on three post-marketing cases that occurred despite the drug's initial approval as a COMT inhibitor. The FDA-mandated monitoring schedule requires liver function tests at baseline before initiating therapy, then every two weeks for the first six months of treatment, then monthly for the following six months, and then every eight weeks thereafter. The threshold for discontinuation is an ALT or AST elevation above two times the upper limit of normal at any point during monitoring — a relatively conservative threshold that reflects the severity of the hepatotoxicity risk. Because of this intensive monitoring burden and the underlying hepatotoxicity risk, tolcapone is reserved for patients who have not obtained adequate benefit from entacapone and opicapone and who are both willing and able to adhere to the monitoring protocol.
Option A: Option A is incorrect because annual monitoring is wholly inadequate for tolcapone; the required interval is every two weeks during the initial six months, not annually, and the ALT/AST threshold for discontinuation is two times the upper limit of normal, not five times — the five-times threshold is a common trigger point for other hepatotoxic drugs but not for tolcapone.
Option B: Option B is incorrect because the monitoring schedule is far more intensive than every six months, particularly in the first year; the black-box warning mandates biweekly testing for the first six months alone, not biannual.
Option D: Option D is incorrect because symptom-triggered testing is explicitly insufficient for tolcapone; the black-box warning requires routine, scheduled monitoring regardless of symptoms, precisely because hepatotoxicity can advance rapidly and may not present with warning symptoms until liver failure is well established.
Option E: Option E is incorrect because monthly monitoring throughout all of therapy is not the specified schedule — the correct schedule reduces in frequency from every two weeks to monthly and then to every eight weeks as therapy continues, reflecting the highest-risk period in the early months.
15. Which of the following best describes the pharmacokinetic mechanism by which peripheral COMT inhibitors such as entacapone extend the therapeutic effect of each levodopa dose in patients with Parkinson's disease?
A) Peripheral COMT inhibitors block the large neutral amino acid transporter in the intestinal wall, increasing levodopa absorption and reducing the dose-to-dose variability that drives wearing-off symptoms
B) Peripheral COMT inhibitors inhibit aromatic amino acid decarboxylase in the periphery, reducing the conversion of levodopa to dopamine before it crosses the blood-brain barrier and thereby increasing the fraction reaching CNS tissue
C) Peripheral COMT inhibitors compete with levodopa for binding to plasma proteins, releasing bound levodopa into the free fraction and transiently increasing CNS penetration during the post-dose period
D) Peripheral COMT inhibitors induce CYP3A4 in the liver, accelerating the clearance of 3-O-methyldopa and thereby reducing its competition with levodopa for transport across the blood-brain barrier
E) Peripheral COMT inhibitors block the methylation of levodopa to 3-O-methyldopa (3-OMD), reducing a major levodopa degradation pathway, increasing the levodopa area under the plasma concentration-time curve (AUC), and extending the duration of meaningful plasma levodopa exposure after each dose
ANSWER: E
Rationale:
Option E is correct. Catechol-O-methyltransferase (COMT) methylates levodopa in peripheral tissues to form 3-O-methyldopa (3-OMD), a metabolite that crosses the blood-brain barrier but has no antiparkinsonian activity and may compete with levodopa for transport into the CNS via the large neutral amino acid transporter. By inhibiting peripheral COMT, drugs such as entacapone reduce 3-OMD formation, preserve a larger fraction of each levodopa dose in its active form, and increase the area under the levodopa plasma concentration-time curve (AUC). The net clinical effect is a prolongation of the therapeutic window after each levodopa dose — more levodopa reaches the brain for a longer period — which reduces wearing-off episodes without requiring an increase in the levodopa dose itself. This is the mechanistic foundation for using COMT inhibitors as adjuncts in levodopa-treated patients with motor fluctuations.
Option A: Option A is incorrect because peripheral COMT inhibitors do not act on the large neutral amino acid transporter; while competition at this transporter is relevant to dietary protein interactions with levodopa, COMT inhibitors address a different step in levodopa's metabolic pathway — peripheral methylation — not transporter-mediated absorption.
Option B: Option B is incorrect because aromatic amino acid decarboxylase inhibition is the mechanism of carbidopa and benserazide, which are co-administered with levodopa precisely to reduce peripheral conversion to dopamine. COMT inhibitors do not inhibit aromatic amino acid decarboxylase and work through an entirely separate enzymatic pathway.
Option C: Option C is incorrect because levodopa has minimal plasma protein binding and COMT inhibitors do not alter its protein binding; the mechanism is enzymatic catabolism inhibition, not displacement from binding sites.
Option D: Option D is incorrect because peripheral COMT inhibitors do not induce CYP3A4 or accelerate 3-OMD clearance; they reduce 3-OMD formation by blocking the enzymatic reaction that produces it, not by enhancing its elimination after it has been formed.
16. A 66-year-old woman with Parkinson's disease has been taking carbidopa-levodopa 25/100 mg four times daily and has recently developed mild choreiform movements of her arms during peak levodopa effect. Her neurologist is planning to add entacapone to reduce wearing-off episodes. Which of the following represents the most appropriate management approach when initiating entacapone in this patient?
A) Entacapone should be added at its standard dose of 200 mg with each levodopa dose without any levodopa adjustment, because entacapone's peripheral-only mechanism does not increase central dopaminergic tone
B) Because entacapone will increase levodopa bioavailability — which is pharmacokinetically equivalent to a levodopa dose increase — the levodopa dose should be proactively reduced by 10% to 30% at the time entacapone is started, given that the patient already has dyskinesia
C) Entacapone should be started at a reduced dose of 100 mg per levodopa administration rather than 200 mg, and the dose titrated upward over four weeks while monitoring dyskinesia, since the standard 200 mg dose is reserved for patients without pre-existing dyskinesia
D) The presence of dyskinesia is an absolute contraindication to adding any COMT inhibitor in a levodopa-treated patient, and entacapone should not be initiated until the dyskinesia has been fully controlled with amantadine or levodopa dose reduction alone
E) Entacapone should be added at standard dose and the patient advised to reduce dietary protein intake, because protein restriction will offset the increased levodopa bioavailability and prevent dyskinesia worsening without requiring a formal dose adjustment
ANSWER: B
Rationale:
Option B is correct. When a COMT inhibitor such as entacapone is added to an existing levodopa regimen, it increases levodopa bioavailability by blocking peripheral COMT-mediated methylation to 3-O-methyldopa (3-OMD). The net pharmacokinetic effect is an increase in the levodopa area under the plasma concentration-time curve (AUC) that is functionally equivalent to having received a higher levodopa dose. In a patient who already has dyskinesia — evidence that their striatum is sensitized and that their current levodopa exposure is already near or at the dyskinesia threshold — adding a COMT inhibitor without reducing the levodopa dose will predictably worsen dyskinesia. The established approach is to anticipate this and reduce the levodopa dose by 10% to 30% at the time the COMT inhibitor is initiated. The exact reduction required varies among patients based on disease stage, degree of striatal sensitization, and current levodopa dose; the 10–30% range provides a practical starting framework.
Option A: Option A is incorrect because stating that a peripheral-only mechanism does not increase central dopaminergic tone is pharmacologically misleading; entacapone increases the amount of levodopa available to cross the blood-brain barrier and be converted to dopamine centrally — that is its entire therapeutic purpose, and it unavoidably augments central dopaminergic exposure in the process.
Option C: Option C is incorrect because entacapone does not come in a 100 mg dose and is not titrated from a lower starting dose; the approved formulation is 200 mg co-administered with each levodopa dose, and dose adjustment for dyskinesia management is made to levodopa, not to entacapone.
Option D: Option D is incorrect because pre-existing dyskinesia is not an absolute contraindication to adding a COMT inhibitor; it is an indication that a levodopa dose reduction is required when doing so, but the combination of COMT inhibitor plus adjusted levodopa dose is a standard and appropriate management strategy in patients with motor fluctuations and dyskinesia.
Option E: Option E is incorrect because dietary protein restriction addresses a different pharmacokinetic interaction — amino acid competition with levodopa at the large neutral amino acid transporter — and is not an appropriate substitute for the formal dose adjustment needed when adding a COMT inhibitor to a patient with dyskinesia.
17. A 72-year-old man with Parkinson's disease taking rasagiline 1 mg daily is admitted for an elective hip replacement. The anesthesiologist asks whether meperidine can be used for post-operative pain management. Which of the following is the most appropriate response?
A) Meperidine is absolutely contraindicated with all MAO-B inhibitors including rasagiline, due to risk of a potentially fatal syndrome involving hyperpyrexia, rigidity, and CNS excitation; alternative analgesics must be used
B) Meperidine can be used safely at reduced doses in patients taking rasagiline because rasagiline's selectivity for MAO-B leaves MAO-A intact, and the meperidine interaction risk applies only to non-selective MAOIs that inhibit both isoforms
C) Meperidine is safe to use with rasagiline provided rasagiline is held for 24 hours before surgery, since rasagiline's short plasma half-life means MAO-B activity will recover fully within that window
D) Meperidine may be used with rasagiline only if the dose is reduced by 50% and the patient is monitored in an intensive care unit for the first 12 hours post-operatively; full-dose meperidine remains absolutely contraindicated
E) The meperidine interaction applies only to selegiline and safinamide because of their amphetamine metabolites and glutamate pathway effects respectively; rasagiline lacks these mechanisms and the interaction risk does not apply to it
ANSWER: A
Rationale:
Option A is correct. Meperidine is absolutely contraindicated with all MAO-B inhibitors as a class — selegiline, rasagiline, and safinamide — regardless of dose, formulation, or the specific agent. The interaction produces a potentially life-threatening syndrome characterized by hyperpyrexia, severe agitation, rigidity, and CNS excitation that resembles serotonin syndrome; the reaction may also involve the accumulation of normeperidine, the active and excitatory metabolite of meperidine. This contraindication applies even at therapeutic doses of the MAO-B inhibitor and even if the MAO-B inhibitor is temporarily held, because MAO-B recovery requires new enzyme synthesis over approximately two to three weeks after an irreversible inhibitor such as rasagiline is stopped. The anesthesia team must be informed, and alternative opioid analgesics — such as hydromorphone, oxycodone, or fentanyl, with appropriate awareness of any residual serotonergic drug interactions — should be substituted.
Option B: Option B is incorrect because the meperidine interaction is a class contraindication for all selective MAO-B inhibitors, not only non-selective MAOIs; the interaction mechanism involves serotonergic pathways and normeperidine accumulation, not MAO-A-mediated effects, and MAO-B selectivity does not protect against it.
Option C: Option C is incorrect because holding rasagiline for 24 hours before surgery does not restore MAO-B activity; rasagiline is an irreversible, covalent inhibitor, and recovery of MAO-B activity requires de novo enzyme synthesis over two to three weeks — a 24-hour hold period is completely insufficient to remove the contraindication.
Option D: Option D is incorrect because there is no approved reduced-dose meperidine protocol that renders the combination safe with any MAO-B inhibitor; the contraindication is absolute and is not modified by dose reduction or monitoring intensity.
Option E: Option E is incorrect because the meperidine contraindication is not mechanistically related to amphetamine metabolites (a selegiline property) or to glutamate pathways (a safinamide property); it applies to rasagiline equally and is a class-wide absolute contraindication regardless of each agent's individual pharmacological characteristics.
18. The SETTLE trial evaluated safinamide as an adjunct to carbidopa-levodopa in patients with mid-to-late stage Parkinson's disease and motor fluctuations. Which of the following correctly describes the primary finding and its significance?
A) The SETTLE trial found that safinamide 100 mg daily significantly reduced dyskinesia frequency compared to placebo, establishing it as the first MAO-B inhibitor with a proven anti-dyskinetic effect superior to levodopa dose reduction alone
B) The SETTLE trial demonstrated that safinamide 50 mg daily produced equivalent on-time improvement to entacapone 200 mg per levodopa dose, supporting its use as a once-daily alternative with a simpler dosing schedule
C) The SETTLE trial showed that safinamide 100 mg daily improved UPDRS motor scores during off periods by approximately 30% compared to placebo, confirming that its sodium channel mechanism reduces off-period severity independently of MAO-B inhibition
D) The SETTLE trial found that safinamide 100 mg daily significantly increased daily on time without troublesome dyskinesia by approximately 1.42 hours compared to placebo, with dyskinesia ratings not worsening relative to placebo over 24 weeks
E) The SETTLE trial demonstrated that safinamide was inferior to rasagiline for off-time reduction but superior for dyskinesia control, establishing the two agents as complementary with rasagiline preferred for off-time and safinamide preferred for dyskinesia management
ANSWER: D
Rationale:
Option D is correct. The SETTLE trial (Schapira et al., 2017) was a randomized, double-blind, placebo-controlled trial of safinamide 100 mg daily added to a stable carbidopa-levodopa regimen in patients with mid-to-late stage Parkinson's disease and motor fluctuations. The primary endpoint was change from baseline in daily on time without troublesome dyskinesia. After 24 weeks, safinamide significantly increased daily on time without troublesome dyskinesia by approximately 1.42 hours compared to placebo, a clinically meaningful improvement. Importantly, dyskinesia ratings did not worsen relative to placebo — a finding consistent with the hypothesis that safinamide's anti-glutamatergic sodium channel mechanism may contribute to dyskinesia attenuation even as dopaminergic exposure is augmented. Adverse events were consistent with dopaminergic augmentation overall, including dyskinesia and nausea, but were not substantially different in frequency from other levodopa adjuncts.
Option A: Option A is incorrect because the SETTLE trial did not demonstrate that safinamide significantly reduced dyskinesia frequency compared to placebo; the finding was that dyskinesia did not worsen relative to placebo — a preservation of dyskinesia control that distinguished it favorably from what might be expected when adding a dopaminergic adjunct, not a reduction below baseline dyskinesia rates.
Option B: Option B is incorrect because the SETTLE trial compared safinamide against placebo, not against entacapone, and at the 100 mg dose, not 50 mg; no head-to-head equivalence comparison with entacapone was the design or primary conclusion of the SETTLE trial.
Option C: Option C is incorrect because the SETTLE trial's primary endpoint was on time without troublesome dyskinesia, not UPDRS motor scores during off periods; while UPDRS data were collected, the trial's design and principal finding centered on the on-time metric, and the description of a 30% off-period improvement is not the study's reported primary result.
Option E: Option E is incorrect because the SETTLE trial did not include a rasagiline comparator arm; it was a placebo-controlled trial of safinamide, and no direct efficacy comparison between safinamide and rasagiline was made in this study.
19. A neurologist decides to add rasagiline to the regimen of a patient with Parkinson's disease who is already taking carbidopa-levodopa and entacapone. Which of the following best describes why this triple combination is pharmacologically rational, and what clinical precaution it requires?
A) The combination is rational because rasagiline inhibits CYP1A2, thereby reducing entacapone's hepatic metabolism and extending its duration of action; the precaution is that the entacapone dose must be halved to avoid COMT over-inhibition
B) The combination is rational because rasagiline and entacapone compete for the same COMT active site and their combined occupancy produces non-competitive enzyme inhibition; the precaution is monthly liver function monitoring due to the hepatotoxicity risk of dual enzyme blockade
C) The combination is rational because the two mechanisms are additive — rasagiline reduces dopamine catabolism in the striatum via MAO-B inhibition while entacapone increases levodopa AUC via peripheral COMT inhibition; the precaution is that a more substantial levodopa dose reduction may be needed than with either adjunct alone
D) The combination is rational because rasagiline converts some of its effect to COMT inhibition at higher synaptic dopamine concentrations, complementing entacapone's peripheral action; the precaution is that tyramine dietary restriction is required when both drugs are used together
E) The combination is irrational because MAO-B inhibition and COMT inhibition share the same downstream effect on levodopa pharmacokinetics, making the addition of a second adjunct redundant without adding clinical benefit while doubling the risk of drug interactions
ANSWER: C
Rationale:
Option C is correct. The combination of an MAO-B inhibitor with a peripheral COMT inhibitor is both pharmacologically rational and widely used in clinical practice. The two drug classes address dopaminergic augmentation through genuinely distinct and complementary mechanisms: COMT inhibitors such as entacapone act peripherally to block the methylation of levodopa to 3-O-methyldopa (3-OMD), increasing the levodopa AUC that reaches the brain; MAO-B inhibitors such as rasagiline act centrally in the striatum to slow the oxidative catabolism of dopamine after it has been formed from levodopa. Because the mechanisms are additive in their net effect of extending dopaminergic exposure, combining them can provide greater off-time reduction than either agent alone. The STRIDE-PD trial examined early initiation of carbidopa-levodopa-entacapone and confirmed the combination's tolerability. The critical management implication is that when both adjuncts are added simultaneously or when a second adjunct is added to an existing single-adjunct regimen, the cumulative increase in dopaminergic exposure is larger than with either agent alone, and a more substantial levodopa dose reduction should be anticipated — particularly in patients with pre-existing dyskinesia.
Option A: Option A is incorrect because rasagiline does not inhibit CYP1A2; rasagiline is a substrate of CYP1A2 (and susceptible to inhibition by drugs such as ciprofloxacin), but it is not itself an inhibitor of this isoform.
Option B: Option B is incorrect because rasagiline inhibits MAO-B and entacapone inhibits COMT — these are entirely different enzymes with no shared active site; there is no combined enzyme inhibition interaction between them, and the hepatotoxicity monitoring requirement applies to tolcapone, not entacapone.
Option D: Option D is incorrect because rasagiline does not acquire COMT-inhibitory properties at any concentration; its mechanism is exclusively MAO-B inhibition, and MAO-B inhibitors do not exhibit any COMT activity under any pharmacological circumstances; additionally, tyramine dietary restriction is not required when MAO-B inhibitors and COMT inhibitors are combined.
Option E: Option E is incorrect because calling the combination irrational based on shared downstream effects misrepresents the pharmacology; the mechanisms are genuinely distinct — one operates on levodopa peripheral metabolism and the other on central dopamine catabolism — and their combination has demonstrated clinical utility.
20. A pharmacist is counseling a patient newly prescribed selegiline tablets 5 mg twice daily as an adjunct to carbidopa-levodopa. Regarding timing of doses, which of the following instructions is most pharmacologically justified and clinically important?
A) Both doses should be taken at bedtime to maximize overnight MAO-B inhibition during the period when levodopa concentrations are lowest and dopamine turnover is highest
B) The two daily doses should be taken with meals — one at breakfast and one at dinner — because food significantly increases selegiline bioavailability and reduces peak amphetamine metabolite concentrations
C) Selegiline should be taken at the same times as each carbidopa-levodopa dose, because co-administration is required to activate MAO-B inhibition and the two drugs must be present in the circulation simultaneously to produce a synergistic effect
D) The timing of selegiline doses is pharmacologically irrelevant because its irreversible MAO-B inhibition is already sustained 24 hours a day after the first week of therapy; only the total daily dose matters, not when individual doses are taken
E) Both doses should be taken in the morning — one at breakfast and one no later than midday — because selegiline's amphetamine metabolites (l-methamphetamine and l-amphetamine) are CNS stimulants that will cause sleep-onset insomnia if the second dose is taken in the afternoon or evening
ANSWER: E
Rationale:
Option E is correct. The timing restriction for selegiline is directly driven by its amphetamine metabolite profile. When the standard oral tablet undergoes hepatic first-pass metabolism, it generates l-methamphetamine and l-amphetamine as active metabolites. These compounds are CNS stimulants with a meaningful duration of action; if the second daily dose is taken in the afternoon or evening, the stimulant metabolites remain pharmacologically active during the hours when the patient would normally be falling asleep, reliably producing sleep-onset insomnia. The clinically established instruction is to take the first dose at breakfast and the second dose no later than midday — typically before lunch — so that the amphetamine metabolite peak and its CNS stimulant effect have largely subsided by bedtime. This timing restriction applies to both the standard tablet and the orally disintegrating tablet (ODT) formulation, although the ODT produces substantially lower amphetamine metabolite concentrations by bypassing first-pass metabolism; even so, the second ODT dose should be taken at lunch, not in the afternoon.
Option A: Option A is incorrect because bedtime dosing of selegiline is precisely the pattern that produces insomnia; the amphetamine metabolites generated from an evening dose would be pharmacologically active during the sleep period, directly causing the adverse effect that the morning-dosing instruction is designed to prevent.
Option B: Option B is incorrect because food does not substantially alter selegiline bioavailability in a clinically meaningful way, and dinner-time dosing of the second dose would reproduce the insomnia problem that the timing instruction is specifically designed to avoid; the rationale for the dosing schedule is metabolite kinetics, not food interactions.
Option C: Option C is incorrect because selegiline does not require co-administration with levodopa to exert its effect; MAO-B inhibition is an autonomous pharmacological action that occurs regardless of whether levodopa is simultaneously present, and the two drugs do not need to be in the circulation at the same time to produce their individual effects.
Option D: Option D is incorrect because while it is true that irreversible MAO-B inhibition is sustained 24 hours a day after the first week of therapy, the timing of each selegiline dose determines when the amphetamine metabolite peak occurs — and that timing directly affects whether the patient can sleep, making dose timing clinically important even when the MAO-B inhibitory effect is already continuous.
21. A 65-year-old man with Parkinson's disease has been on tolcapone for four months after failing to achieve adequate motor control with entacapone and opicapone. At his scheduled two-week liver function check, his alanine aminotransferase (ALT) is reported at 2.3 times the upper limit of normal. He is asymptomatic and feels well. What is the correct action?
A) Tolcapone must be discontinued immediately; the black-box warning requires stopping the drug if ALT or AST exceeds two times the upper limit of normal at any point during monitoring, regardless of symptoms
B) Tolcapone can be continued at the current dose with repeat liver function testing in two weeks; an ALT of 2.3 times the upper limit of normal is within the acceptable range for continued therapy and should be rechecked before a decision is made
C) The tolcapone dose should be reduced by half and liver function tests repeated in one week; if the ALT returns to below two times the upper limit of normal on the reduced dose, the drug may be continued at the lower dose indefinitely
D) Tolcapone should be held for two weeks and then restarted at its standard dose once liver function tests have normalized; a single transaminase elevation is not a reason for permanent discontinuation provided the patient is asymptomatic
E) The elevated ALT is likely attributable to muscle injury from Parkinson's disease-related falls rather than hepatotoxicity; tolcapone can be continued while repeating the test with a simultaneous creatine kinase measurement to distinguish hepatic from muscle-origin enzyme elevation
ANSWER: A
Rationale:
Option A is correct. The tolcapone black-box warning establishes a clear and non-negotiable threshold for discontinuation: if ALT or AST rises above two times the upper limit of normal at any point during monitoring, tolcapone must be stopped immediately. This threshold is deliberately conservative — set at two times rather than the three-to-five times threshold used for many other hepatotoxic drugs — reflecting the severity of the hepatotoxicity risk and the occurrence of fatal fulminant hepatic failure in post-marketing surveillance. The patient's ALT of 2.3 times the upper limit of normal exceeds this threshold, and the drug must be discontinued regardless of the absence of symptoms. Asymptomatic transaminase elevation does not modify the obligation to stop the drug; the whole purpose of scheduled monitoring is to detect biochemical signals before they evolve into symptomatic liver injury.
Option B: Option B is incorrect because 2.3 times the upper limit of normal exceeds the two-times threshold that mandates discontinuation; continuing the drug and rechecking in two weeks is not consistent with the black-box warning and could allow progression to serious hepatotoxicity.
Option C: Option C is incorrect because there is no approved dose-reduction strategy for managing tolcapone-associated transaminase elevations; the black-box warning does not provide a pathway for dose reduction and continuation once the threshold is exceeded — the drug must be stopped.
Option D: Option D is incorrect because holding and restarting after normalization is not permitted under the tolcapone monitoring protocol; transaminase elevation above the threshold mandates permanent discontinuation, not a temporary hold with later restart.
Option E: Option E is incorrect because attributing the ALT elevation to creatine kinase cross-reactivity or muscle injury is not appropriate without supporting evidence, and in any case does not change the obligation under the black-box warning; when ALT exceeds two times the upper limit of normal during tolcapone therapy, the drug is stopped while the cause is investigated — the investigation does not delay the discontinuation decision.
22. The BIPARK-I and BIPARK-II trials evaluated opicapone in patients with Parkinson's disease and motor fluctuations on levodopa. Which of the following correctly describes their key findings regarding opicapone's efficacy and comparative standing within the COMT inhibitor class?
A) The BIPARK trials demonstrated that opicapone 25 mg once daily was equivalent to entacapone 200 mg per levodopa dose in reducing off time, establishing 25 mg as the preferred starting dose with uptitration to 50 mg reserved for non-responders
B) The BIPARK trials found that opicapone 50 mg daily was significantly superior to entacapone 200 mg per levodopa dose in reducing daily off time, leading to regulatory approval of opicapone as the first-line COMT inhibitor ahead of entacapone
C) The BIPARK trials found that opicapone 50 mg daily reduced daily off time significantly compared to placebo but caused more hepatotoxicity than entacapone in the active comparator arm, leading to a requirement for liver function monitoring similar to tolcapone
D) The BIPARK trials found that opicapone 50 mg daily reduced daily off time by approximately 1.0 to 1.1 hours compared to placebo, with an effect size comparable to entacapone 200 mg three times daily in the active comparator arm, while allowing once-daily bedtime dosing
E) The BIPARK trials primarily evaluated opicapone as a monotherapy in early Parkinson's disease without levodopa, demonstrating its non-inferiority to rasagiline 1 mg daily as an initial treatment option for newly diagnosed patients
ANSWER: D
Rationale:
Option D is correct. The BIPARK-I and BIPARK-II trials were randomized, double-blind, placebo- and active-controlled trials of opicapone 50 mg daily in patients with Parkinson's disease and motor fluctuations on levodopa. Both trials demonstrated that opicapone 50 mg significantly reduced daily off time compared to placebo by approximately 1.0 to 1.1 hours. The active comparator arm, which used entacapone 200 mg co-administered with each levodopa dose (a multiple-times-daily regimen), produced a broadly comparable magnitude of off-time reduction, confirming that opicapone achieves an equivalent clinical effect to entacapone — but with the substantial practical advantage of once-daily bedtime dosing rather than dosing with each levodopa administration. Opicapone also carries no requirement for liver function monitoring, unlike tolcapone, which makes its safety surveillance profile comparable to entacapone while offering superior dosing convenience.
Option A: Option A is incorrect because the approved dose of opicapone is 50 mg once daily, not 25 mg; the BIPARK trials studied the 50 mg dose as the primary therapeutic dose, and 25 mg is not the established starting dose for this agent.
Option B: Option B is incorrect because the BIPARK trials did not demonstrate that opicapone was statistically superior to entacapone in off-time reduction; the finding was comparable efficacy between opicapone 50 mg and entacapone 200 mg multiple times daily — not superiority.
Option C: Option C is incorrect because opicapone, like entacapone, does not penetrate the blood-brain barrier and has not been associated with the hepatotoxicity seen with tolcapone; no liver function monitoring requirement is mandated for opicapone, and the BIPARK trials did not reveal a hepatotoxicity signal.
Option E: Option E is incorrect because the BIPARK trials were conducted in levodopa-treated patients with motor fluctuations, not as monotherapy trials in early untreated Parkinson's disease; and opicapone was not compared to rasagiline in these trials — the active comparator was entacapone.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.